CO2023007851A2 - Proteínas de unión a il-7 y su uso en tratamientos médicos - Google Patents

Proteínas de unión a il-7 y su uso en tratamientos médicos

Info

Publication number
CO2023007851A2
CO2023007851A2 CONC2023/0007851A CO2023007851A CO2023007851A2 CO 2023007851 A2 CO2023007851 A2 CO 2023007851A2 CO 2023007851 A CO2023007851 A CO 2023007851A CO 2023007851 A2 CO2023007851 A2 CO 2023007851A2
Authority
CO
Colombia
Prior art keywords
binding proteins
medical treatments
treatments
medical
interleukin
Prior art date
Application number
CONC2023/0007851A
Other languages
English (en)
Inventor
Gerben Bouma
Edward Thomas Coulstock
David Dixon
Stephanie Hopley
Alan Peter Lewis
Jessica Lynn Neisen
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO2023007851A2 publication Critical patent/CO2023007851A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan proteínas de unión a interleucina 7 (IL-7), composiciones farmacéuticas y su uso en el tratamiento o prevención de una enfermedad o afección.
CONC2023/0007851A 2020-12-02 2023-06-15 Proteínas de unión a il-7 y su uso en tratamientos médicos CO2023007851A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063120564P 2020-12-02 2020-12-02
PCT/EP2021/083465 WO2022117526A1 (en) 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy

Publications (1)

Publication Number Publication Date
CO2023007851A2 true CO2023007851A2 (es) 2023-06-30

Family

ID=78844686

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007851A CO2023007851A2 (es) 2020-12-02 2023-06-15 Proteínas de unión a il-7 y su uso en tratamientos médicos

Country Status (14)

Country Link
US (2) US11802150B2 (es)
EP (1) EP4255928A1 (es)
JP (1) JP2023551935A (es)
KR (1) KR20230098288A (es)
CN (1) CN116547002A (es)
AR (1) AR124286A1 (es)
AU (1) AU2021391493A1 (es)
CA (1) CA3199648A1 (es)
CL (1) CL2023001556A1 (es)
CO (1) CO2023007851A2 (es)
IL (1) IL303134A (es)
MX (1) MX2023006294A (es)
TW (1) TWI821804B (es)
WO (1) WO2022117526A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体

Also Published As

Publication number Publication date
US20220169717A1 (en) 2022-06-02
MX2023006294A (es) 2023-06-13
US11802150B2 (en) 2023-10-31
WO2022117526A1 (en) 2022-06-09
EP4255928A1 (en) 2023-10-11
AU2021391493A1 (en) 2023-06-08
CN116547002A (zh) 2023-08-04
US20240025988A1 (en) 2024-01-25
IL303134A (en) 2023-07-01
KR20230098288A (ko) 2023-07-03
AR124286A1 (es) 2023-03-15
CA3199648A1 (en) 2022-06-09
JP2023551935A (ja) 2023-12-13
AU2021391493A9 (en) 2024-05-23
TW202237183A (zh) 2022-10-01
CL2023001556A1 (es) 2023-11-10
TWI821804B (zh) 2023-11-11

Similar Documents

Publication Publication Date Title
CO2020009625A2 (es) Inhibidor de fap
CY1118519T1 (el) Συνθεση τετρακυκλινων και αναλογων αυτων
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
CA3155883A1 (en) BUCCO-DENTAL CARE COMPOSITIONS BASED ON BETA ACID OF HOPS AND AMINO ACID
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
WO2022167816A3 (en) Antibodies
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
AR122380A1 (es) Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos
MX2022005547A (es) Derivados terapeuticos de interleucina-22.
CR20220374A (es) Métodos de tratamiento de la esplenomegalia
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
WO2021004958A3 (en) Compositions comprising bacterial strains
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
ATE415973T1 (de) Gemeinsame gabe von tigecyclin und digoxin
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2022005251A (es) Conjugados de interleuquina 10 y sus usos.
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv